<DOC>
	<DOC>NCT03054337</DOC>
	<brief_summary>This is a Phase 2, randomized, double-blind, placebo-controlled, dose-finding study to assess the efficacy, safety, tolerability, PK, and PD of orally administered vadadustat in Japanese subjects with anemia secondary to NDD-CKD.</brief_summary>
	<brief_title>Dose-Finding Study of Vadadustat in Japanese Subjects With Anemia Secondary to Non-Dialysis Dependent Chronic Kidney Disease (NDD-CKD)</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<criteria>Male and female Japanese subjects ≥20 years of age Diagnosis of CKD based on an estimated glomerular filtration rate ≤60 mL/min/1.73 m2 Hb ≤10.5 g/dL Not currently being treated with dialysis and not expected to start dialysis within 3 months of screening Anemia due to a cause other than CKD or presence of active bleeding or recent blood loss Sickle cell disease, myelodysplastic syndromes, bone marrow fibrosis, hematologic malignancy, myeloma, hemolytic anemia, thalassemia, or pure red cell aplasia Red blood cell transfusion within 4 weeks prior to or during screening Intravenous iron within 4 weeks prior to or during screening Any use of erythropoiesisstimulating agents within 6 weeks prior to or during screening</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Anemia</keyword>
	<keyword>kidney</keyword>
	<keyword>non-dialysis dependent chronic kidney disease</keyword>
	<keyword>CKD</keyword>
	<keyword>NDD-CKD</keyword>
	<keyword>renal</keyword>
	<keyword>vadadustat</keyword>
	<keyword>AKB-6548</keyword>
	<keyword>hypoxia-inducible factor</keyword>
	<keyword>HIF</keyword>
	<keyword>hypoxia-inducible factor prolyl-hydroxylase inhibitor</keyword>
	<keyword>HIF-PHI</keyword>
	<keyword>Japan</keyword>
	<keyword>Japanese</keyword>
</DOC>